National pharmacy cardiovascular council treatment guidelines for the management of type 2 diabetes mellitus: Toward better patient outcomes and new roles for pharmacists

Pharmacotherapy

Volumn 22, Issue 4, 2002, Pages 436-444

  Hawkins, David ^a   Bradberry, J Chris ^b   Cziraky, Mark J ^c,d,e,f,g,h  

^a MERCER UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c HEALTHCORE INC   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g UNIVERSITY OF ILLINOIS   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ARTICLE; CARDIOVASCULAR FUNCTION; CLINICAL PHARMACY; DRUG MECHANISM; HUMAN; MEDICAL SOCIETY; MEDICARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REIMBURSEMENT; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE, HEALTH, REIMBURSEMENT; PHARMACISTS; PROFESSIONAL ROLE; TREATMENT OUTCOME; UNITED STATES;

EID: 0036211624     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.7.436.33667     Document Type: Article

References (42)

1. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. Adults. The third national health and nutrition examination survey, 1988-1994
2. Diabetes trends in the U.S.: 1990-1998
3. VIII. Study design, progress and performance
4. Economic consequences of diabetes mellitus in the U.S. In 1997
5. Excess costs of medical care for patients with diabetes in a managed care population
6. The cost to health plans of poor glycemic control
7. Potential short-term economic benefits of improved glycemic control: A managed care perspective
8. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia
9. Revisiting nurse knowledge about diabetes: An update and implications for practice
10. Effect of improved glycemic control on health care costs and utilization
11. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled, double-blind trial
12. Standards of medical care for patients with diabetes mellitus
13. The diabetes prevention program: Baseline characteristics of the randomized cohort
14. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
15. The STOP-NIDDM trial: An international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: Rationale, design, and preliminary screening data. Study to prevent non-insulin-dependent diabetes mellitus
16. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
17. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy
18. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
19. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
20. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
21. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
22. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
23. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
24. Ramipril and the development of diabetes
25. The hypertension optimal treatment study and the importance of lowering blood pressure
26. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
27. Management of dyslipidemia in adults with diabetes
28. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
29. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
30. Management of dyslipidemia in adults with diabetes
31. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
32. Intentional weight loss and mortality among overweight individuals with diabetes
33. Promoting early diagnosis and treatment of type 2 diabetes: The National Diabetes Education Program
34. American College of Endocrinology consensus conference on guidelines for glycemic control
35. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
36. The 1999 scope of practice for diabetes educators and the standards of practice for diabetes educators
37. The management of type 2 diabetes mellitus: A call to action for pharmacists
38. Pharmacist compensation for ambulatory patient care services